Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicamtiv in primary dilated cardiomyopathy
2019-003626-24Phase 2Active
- Sponsor
- MyoKardia
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of danicamtiv in dilated cardiomyopathy (DCM) (3 cohorts), sponsored by MyoKardia. Primary endpoint: Clinical safety and tolerability. Started Jan 2020; status: active.
02
Drugs
danicamtiv
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on 2019-003626-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003626-24.